Testing safety of a nose spray for staph bacteria
Part of Infections clinical trials.
This trial tests a new nose spray called HY-133 to see if it's safe and can clear a common type of staph bacteria from the nose. It is for people who have this bacteria but not the antibiotic-resistant kind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a certain type of staph bacteria (MSSA) in your nose, not the resistant type (MRSA).
- You must not have any major health problems like diabetes or heart disease.
- You must not have a runny nose from allergies or other causes.
- You must not have used antibiotics or any nose treatment in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving one versus multiple doses of a special nasal treatment (called nasal microbiota therapy, or NMT) changes the types of helpful bacteria in your baby's nose. The goal is to see if the treatment keeps bad bacteria, like staph, from growing.
This trial studies whether dupilumab (an injection) can reduce staph bacteria in the nose and make the nose’s microbes more diverse in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). If you already have a plan to start dupilumab as standard care, the study may help doctors better understand why it works.
This trial studies the bacteria living in the nose of patients with a staph bloodstream infection. It aims to better understand why some infections persist, which could lead to better treatments.
This study tests whether giving a nasal spray of healthy bacteria to infants can restore good germs in the nose after they receive mupirocin ointment to treat Staph aureus. It aims to bring back a healthy nasal microbiome.
This trial tests a nasal spray called VVN432 in healthy volunteers and people with chronic sinusitis. It checks if the spray is safe and how the body processes it.
This early-stage trial tests a new nasal spray combining stem cell-derived material, an antibiotic, and an enzyme to treat chronic sinus infections caused by a specific bacteria. The goal is to reduce inflammation and infection in people who have had symptoms for over 3 months.
Hear when a new Staphylococcus Aureus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.